Jordan Ellis
The Memorial Sloan Kettering Cancer Center (MSK or MSKCC) is a cancer treatment and research institution in Manhattan, New York City. The hospital was founded in 1884 as the New York Cancer Hospital and was the first institution in the United States devoted exclusively to cancer treatment. In 1945, the Sloan Kettering Institute was founded by Alfred P. Sloan and Charles F. Kettering, and in 1980, the Memorial Hospital and the Sloan-Kettering Institute merged to form the Memorial Sloan Kettering Cancer Center.
| Characteristics | Values |
|---|---|
| Year of establishment | 1945 |
| Namesake | Alfred P. Sloan and Charles F. Kettering |
| Type of institute | Cancer research |
| Type of entity | Separate from Memorial Hospital until 1980 |
| Location | Adjacent to Memorial Hospital |
| Donor | Alfred P. Sloan |
| Donation amount | $4 million |
| Donor's position | Chairman of General Motors |
Explore related products
What You'll Learn
Memorial Hospital for the Treatment of Cancer and Allied Diseases
The Memorial Sloan Kettering Cancer Center (MSK or MSKCC) is a cancer treatment and research institution in Manhattan, New York City. The hospital was founded in 1884 as the New York Cancer Hospital on the Upper West Side of Manhattan. In 1899, the name was changed to the General Memorial Hospital for the Treatment of Cancer and Allied Diseases. In 1916, the hospital dropped the word "General" from its name and became known as the Memorial Hospital for the Treatment of Cancer and Allied Diseases.
The hospital was founded by a group that included John Jacob Astor III and his wife, Charlotte. They appointed William B. Coley as an attending surgeon, who pioneered an early form of immunotherapy to eradicate tumours. Around 1910, James Ewing, a professor at Cornell University's medical college, established a collaboration with Memorial Hospital with the help of funding from industrialist and philanthropist James Douglas. Douglas' funding and enthusiasm for the development of radiation therapy inspired Ewing to become one of the pioneers in this field of treatment.
In 1934, John D. Rockefeller Jr. donated land on York Avenue for a new location, and in 1936, Memorial Hospital began its move, officially reopening at the new location in 1939. In 1945, the Sloan-Kettering Institute for Cancer Research was founded by Alfred P. Sloan, the chairman of General Motors, and Charles F. Kettering, the vice president and director of research at General Motors. The institute was built adjacent to Memorial Hospital, and in 1960, the Memorial Sloan Kettering Cancer Center was formed as a new corporation to coordinate the two institutions. Finally, in 1980, Memorial Hospital and the Sloan-Kettering Institute merged into a single entity under the name Memorial Sloan Kettering Cancer Center.
Code Blue: Hospital Emergency Response Explained
You may want to see also
Explore related products
![The Kettering Incident (Series 1) [ NON-USA FORMAT, PAL, Reg.0 Import - Australia ]](https://m.media-amazon.com/images/I/815o8YAARCL._AC_UY218_.jpg)
Sloan-Kettering Institute for Cancer Research
The Sloan-Kettering Institute for Cancer Research, now known as Memorial Sloan Kettering Cancer Center, was founded in 1945 by Alfred P. Sloan and Charles F. Kettering. Sloan was the chairman of General Motors and a trustee of Memorial Hospital, and Kettering was vice president and director of research at General Motors. Sloan donated $4 million to create the institute through his Sloan Foundation (now known as the Alfred P. Sloan Foundation). Kettering personally oversaw the organisation of a cancer research program based on industrial techniques.
The Sloan-Kettering Institute was originally a separate entity from Memorial Hospital, with its own management and board. However, the two institutions were adjacent to each other and began coordinating their operations in 1960 under the name Memorial Sloan Kettering Cancer Center. In 1980, they formally merged into a single entity with a single president and CEO.
The Sloan-Kettering Institute has been a leader in cancer research and treatment. Its researchers have made important contributions to the fundamental understanding of human biology and have driven practice-changing innovations in cancer treatment. They have discovered cancer-linked genes, unravelled signalling pathways that control cell growth and division, and identified cells involved in mounting and repressing immune responses.
The institute's commitment to basic science and preclinical research has been a key factor in its success. It has also fostered a spirit of multidisciplinary collaboration, working closely with outstanding clinical investigators at Memorial Hospital. Together, the two institutions have advanced the understanding and treatment of cancer, with Memorial Sloan Kettering Cancer Center ranking as one of the top hospitals for cancer care in the United States.
The Nature of Sacred Heart Hospital: Non-Profit or For-Profit?
You may want to see also
Sloan and Charles F. Kettering
Sloan Kettering Cancer Center is named after Alfred P. Sloan and Charles F. Kettering, two General Motors executives who joined forces in 1945 to establish the Sloan Kettering Institute (SKI), a leading biomedical research institution. Sloan was the chairman of General Motors and a trustee of Memorial Hospital, while Kettering was the vice president and director of research at General Motors. Sloan donated $4 million to create the institute through his Sloan Foundation, and Kettering personally oversaw the organisation of a cancer research program based on industrial techniques. The institute was originally a separate entity from Memorial Hospital, with its own management and board, but the two formally merged in 1980 to become the Memorial Sloan Kettering Cancer Center.
The Sloan Kettering Institute has been at the forefront of cancer research and treatment innovations since its inception. Its researchers have made significant contributions to the fundamental understanding of human biology and have driven practice-changing innovations in cancer treatment. They have discovered cancer-linked genes, unravelled signalling pathways that control cell growth and division, and identified cells involved in mounting and repressing immune responses. The institute's commitment to basic science and preclinical research has led to important advancements in the fight against cancer.
Alfred P. Sloan was a philanthropist, industrialist, and chairman of General Motors. Through his Sloan Foundation (also known as the Alfred P. Sloan Foundation), he donated $4 million (equivalent to $69.9 million in 2024) to establish the Sloan Kettering Institute for Cancer Research. This donation reflects Sloan's commitment to supporting cancer research and improving patient care.
Charles F. Kettering was an inventor, industrialist, and the vice president and director of research at General Motors. He played a crucial role in overseeing the organisation of a cancer research program at the Sloan Kettering Institute. Kettering brought his expertise in industrial techniques to the development of the research program, leveraging his experience in innovation and problem-solving to advance cancer research.
The Memorial Sloan Kettering Cancer Center, formed by the merger of Memorial Hospital and the Sloan Kettering Institute, has built on the legacy of Sloan and Kettering by becoming a leading cancer treatment and research institution. It has been recognised as one of the top "Best Hospitals for Cancer" and is known for its sole focus on cancer treatment and research. The centre's surgeons perform more cancer operations than any other hospital in the nation and have pioneered surgical innovations such as minimally invasive surgery for cancer treatment.
Hospitalizations in New York: A Concerning Trend
You may want to see also
The institute's research and discoveries
Sloan Kettering Institute is named after Alfred P. Sloan and Charles F. Kettering. Sloan was the chairman of General Motors and a trustee on the board of Memorial Hospital, while Kettering was the vice president and director of research at General Motors. Sloan donated $4 million to launch the institute through his Alfred P. Sloan Foundation.
The Sloan Kettering Institute (SKI) is the basic and translational research arm of Memorial Sloan Kettering Cancer Center. The institute has been a hub for biological research within the larger cancer center. It fosters a mix of "basic science" and "translational science". Basic science refers to research that aims to expand human knowledge about fundamental biological processes. On the other hand, translational science turns discoveries into new treatments and diagnostic tools.
Over the last seven and a half decades, researchers at SKI have made significant contributions to the fundamental understanding of human biology and driven practice-changing innovations in cancer treatment. Scientists at SKI have discovered cancer-linked genes, unravelled signalling pathways that control cell growth and division, and identified cells involved in mounting and repressing immune responses. They have also illuminated how vesicles transport molecules to the cell surface for secretion, which later earned a Nobel Prize.
SKI researchers have also figured out how to derive dopamine-producing neurons from human embryonic stem cells, setting the stage for new treatments for Parkinson's disease. They have also uncovered an alternative to the famous Krebs cycle, the process that supplies the energy needs of cells.
In addition, SKI has pioneered surgical innovations, including minimally invasive surgery for the treatment of many cancers. Its radiation oncologists have developed and put into clinical practice leading-edge technologies and techniques in radiation therapy, such as intensity-modulated radiation therapy and proton therapy.
In 1985, researchers at Memorial Sloan Kettering Cancer Center purified human G-CSF. In 1986, the center patented the method of producing and using human G-CSF under the name "human hematopoietic pluripotent colony-stimulating factor" (P-CSF). In 2015, the center opened the Josie Robertson Surgery Center for outpatient surgeries, and in 2017, the FDA approved an MSK-developed immunotherapy, CAR-T, for certain applications in leukemia and lymphoma.
Fetal Heart Tones: When to Expect the First Hospital Check
You may want to see also
The institute's formation and history
The Memorial Sloan Kettering Cancer Center (MSK or MSKCC) was formed in 1980 from the merger of the Memorial Hospital for the Treatment of Cancer and Allied Diseases and the Sloan-Kettering Institute for Cancer Research, founded in 1945. The hospital was founded in 1884 as the New York Cancer Hospital on Manhattan's Upper West Side. John J. Astor and his wife, Charlotte, were among the founders of the hospital, which was the first institution in the United States devoted exclusively to cancer treatment.
In 1899, the name was changed to the General Memorial Hospital for the Treatment of Cancer and Allied Diseases, and in 1916, it became the Memorial Hospital for the Treatment of Cancer and Allied Diseases. John D. Rockefeller Jr. donated land on York Avenue for the hospital's new location in 1934, and it moved to its present location in 1936, opening in 1939.
In 1945, Alfred P. Sloan, chairman of General Motors, donated $4 million to create the Sloan-Kettering Institute through his Sloan Foundation. Charles F. Kettering, GM's vice president and director of research, agreed to oversee the organization of a cancer research program. The institute, dedicated to biomedical research on cancer, was established next to the Memorial Hospital.
In 1960, a new corporate entity, the Memorial Sloan Kettering Cancer Center, was formed to coordinate the two institutions, and in 1980, they were officially unified under a single president and CEO. Over the years, MSK has expanded its outpatient facilities and services to meet the growing needs of its patients, physicians, and researchers. Today, it is a world leader in patient care, research, and educational programs.
Anesthesia Groups: Meeting Hospital's Expectations and Priorities
You may want to see also
Frequently asked questions
The hospital is named after Alfred P. Sloan and Charles F. Kettering, two General Motors executives who joined forces to establish the Sloan Kettering Institute in 1945.
Alfred P. Sloan was the chairman of General Motors and a trustee on the board of Memorial Hospital. He donated $4 million to create the Sloan-Kettering Institute for Cancer Research through his Sloan Foundation.
Charles F. Kettering was the vice president and director of research at General Motors. He personally agreed to oversee the organization of a cancer research program based on industrial techniques.
The Sloan Kettering Institute and Memorial Hospital formally merged in 1980 to become Memorial Sloan Kettering Cancer Center.
